首页 > 最新文献

Current Hypertension Reviews最新文献

英文 中文
Exploring the Challenges of Recruiting Older People for a Randomised Trial Assessing the Feasibility of Treating White Coat Hypertension in the UK General Practices: A Mixed-methods study. 探索招募老年人参与随机试验的挑战,评估在英国全科诊所治疗白大衣高血压的可行性:混合方法研究。
IF 1.5 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-08-19 DOI: 10.2174/0115734021299574240809114921
Ekow Mensah, Khalid Ali, Michael Okorie, Stephen Bremner, Colin McAlister, Nicky Perry, Chakravarthi Rajkumar

Introduction: There is a recognised association between white coat hypertension (WCH) and adverse cardiovascular outcomes in older adults. However, there is no consensus on the management of WCH in this group. The objective of the Hypertension in the Very Elderly Trial (HYVET-2) study was to assess the feasibility of randomising 100 patients > 75years with WCH from General Practice in the UK to treatment or usual care. The study did not randomise any patients. In this follow-up study, we sought to explore the reasons for not recruiting.

Methods: Furthermore, using a mixed-methods study design, staff from 29 General Practice (GP) sites and the Clinical Research Network (CRN) in Kent, Surrey, and Sussex (KSS), UK, were sent an online questionnaire about local research facilities and infrastructure, and HYVET-2 study methodology and target population demographics.

Results: Nineteen (19) individuals responded to the online questionnaires (15 primary care staff, 4 CRN staff). Moreover, using a framework approach, we identified six themes summarising challenges to HYVET-2 recruitment. These themes are established approaches of primary care towards managing WCH in older people, target patient demographics, study design complexity, patient- facing study documents, limited research resources in primary care, and identification of eligible patients using existing coding.

Conclusion: Our experience showed that recruiting older people from primary care to a WCH study was not feasible. A national scoping survey amongst primary care physicians in the UK, as well as robust patient and public involvement (PPI) targeting older people with WCH, might improve recruitment in future studies addressing the management of WCH in older people.

简介:白大衣高血压(WCH)与老年人心血管疾病的不良后果之间存在公认的联系。然而,目前对这一群体的白大衣高血压管理尚未达成共识。高龄老人高血压试验(HYVET-2)研究的目的是评估将英国普通诊所的 100 名 75 岁以上白大衣高血压患者随机分配到治疗或常规护理的可行性。该研究没有对任何患者进行随机治疗。在这项后续研究中,我们试图探索未招募患者的原因:此外,我们还采用了混合方法研究设计,向英国肯特郡、萨里郡和萨塞克斯郡(KSS)的29个全科诊所(GP)和临床研究网络(CRN)的工作人员发送了一份在线问卷,内容涉及当地的研究设施和基础设施、HYVET-2研究方法和目标人群的人口统计数据:共有 19 人(15 名初级保健人员和 4 名 CRN 人员)回复了在线问卷。此外,通过框架方法,我们确定了六个主题,概括了 HYVET-2 招募工作面临的挑战。这些主题包括:基层医疗机构管理老年人妇女儿童疾病的既定方法、目标患者的人口统计学特征、研究设计的复杂性、面向患者的研究文件、基层医疗机构有限的研究资源以及使用现有编码识别符合条件的患者:我们的经验表明,从基层医疗机构招募老年人参与 WCH 研究是不可行的。在英国的初级保健医生中开展全国范围的调查,以及针对患有WCH的老年人开展强有力的患者和公众参与(PPI),可能会改善未来针对老年人WCH管理的研究的招募情况。
{"title":"Exploring the Challenges of Recruiting Older People for a Randomised Trial Assessing the Feasibility of Treating White Coat Hypertension in the UK General Practices: A Mixed-methods study.","authors":"Ekow Mensah, Khalid Ali, Michael Okorie, Stephen Bremner, Colin McAlister, Nicky Perry, Chakravarthi Rajkumar","doi":"10.2174/0115734021299574240809114921","DOIUrl":"https://doi.org/10.2174/0115734021299574240809114921","url":null,"abstract":"<p><strong>Introduction: </strong>There is a recognised association between white coat hypertension (WCH) and adverse cardiovascular outcomes in older adults. However, there is no consensus on the management of WCH in this group. The objective of the Hypertension in the Very Elderly Trial (HYVET-2) study was to assess the feasibility of randomising 100 patients > 75years with WCH from General Practice in the UK to treatment or usual care. The study did not randomise any patients. In this follow-up study, we sought to explore the reasons for not recruiting.</p><p><strong>Methods: </strong>Furthermore, using a mixed-methods study design, staff from 29 General Practice (GP) sites and the Clinical Research Network (CRN) in Kent, Surrey, and Sussex (KSS), UK, were sent an online questionnaire about local research facilities and infrastructure, and HYVET-2 study methodology and target population demographics.</p><p><strong>Results: </strong>Nineteen (19) individuals responded to the online questionnaires (15 primary care staff, 4 CRN staff). Moreover, using a framework approach, we identified six themes summarising challenges to HYVET-2 recruitment. These themes are established approaches of primary care towards managing WCH in older people, target patient demographics, study design complexity, patient- facing study documents, limited research resources in primary care, and identification of eligible patients using existing coding.</p><p><strong>Conclusion: </strong>Our experience showed that recruiting older people from primary care to a WCH study was not feasible. A national scoping survey amongst primary care physicians in the UK, as well as robust patient and public involvement (PPI) targeting older people with WCH, might improve recruitment in future studies addressing the management of WCH in older people.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142005511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The New Editor-In-Chief Note. 新主编说明。
IF 1.5 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-08-16 DOI: 10.2174/0115734021342701240815102008
Guido Grassi
{"title":"The New Editor-In-Chief Note.","authors":"Guido Grassi","doi":"10.2174/0115734021342701240815102008","DOIUrl":"https://doi.org/10.2174/0115734021342701240815102008","url":null,"abstract":"","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142005512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment of Hypertension in Children. 治疗儿童高血压。
IF 1.5 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2024-07-24 DOI: 10.2174/0115734021305332240712103602
Francesca Mainieri, Veronica Maria Tagi, Francesco Chiarelli

Hypertension is a real problem in children. It shows a tracking behaviour, representing a key risk factor for hypertension, cardiovascular disease, and end-organ failure in adulthood. However, the importance of addressing arterial hypertension in children is not limited to its risk of tracking into adulthood. Thus, early detection and management are crucial. Hypertension may be primary or due to secondary causes, and identification of this distinction is very important for the treatment setting. Importantly, the management of hypertension in children is crucial to prevent the well-known cardiovascular effects in adulthood. As demonstrated in the literature, healthy eating habits, together with regular physical activity, can have a major impact on reducing high blood pressure and preventing organ damage in children and adolescents. However, suppose these are not sufficient to treat hypertension. In that case, if patients are symptomatic and/or have additional metabolic conditions such as obesity, type diabetes mellitus, or chronic kidney disease, anti-hypertensive medication must be started. Recent guidelines have provided clear guidance on the treatment of hypertension and hypertensive crisis in pediatric age. On the other hand, there are currently few specific recommendations on the treatment of isolated nocturnal hypertension and treatment-resistant hypertension. This review aims to summarize the most recent recommendations for the treatment of hypertension and hypertensive crisis in children and the last years' knowledge and experience in treating childhood isolated nocturnal hypertension and resistant hypertension of childhood.

高血压是儿童面临的一个现实问题。它具有追踪行为,是成年后高血压、心血管疾病和内脏衰竭的关键风险因素。然而,解决儿童动脉高血压问题的重要性并不仅限于其成年后的追踪风险。因此,早期发现和管理至关重要。高血压可能是原发性的,也可能是继发性的,识别这种区别对治疗非常重要。重要的是,儿童高血压的管理对于预防成年后众所周知的心血管影响至关重要。文献表明,健康的饮食习惯和有规律的体育锻炼对降低儿童和青少年的高血压和预防器官损伤有重要影响。然而,假设这些还不足以治疗高血压。在这种情况下,如果患者有症状和/或伴有其他代谢疾病,如肥胖、糖尿病或慢性肾病,就必须开始服用抗高血压药物。最近的指南为治疗儿科高血压和高血压危象提供了明确的指导。另一方面,目前几乎没有关于治疗孤立性夜间高血压和耐药性高血压的具体建议。本综述旨在总结治疗儿童高血压和高血压危象的最新建议,以及过去几年治疗儿童孤立性夜间高血压和儿童耐药性高血压的知识和经验。
{"title":"Treatment of Hypertension in Children.","authors":"Francesca Mainieri, Veronica Maria Tagi, Francesco Chiarelli","doi":"10.2174/0115734021305332240712103602","DOIUrl":"https://doi.org/10.2174/0115734021305332240712103602","url":null,"abstract":"<p><p>Hypertension is a real problem in children. It shows a tracking behaviour, representing a key risk factor for hypertension, cardiovascular disease, and end-organ failure in adulthood. However, the importance of addressing arterial hypertension in children is not limited to its risk of tracking into adulthood. Thus, early detection and management are crucial. Hypertension may be primary or due to secondary causes, and identification of this distinction is very important for the treatment setting. Importantly, the management of hypertension in children is crucial to prevent the well-known cardiovascular effects in adulthood. As demonstrated in the literature, healthy eating habits, together with regular physical activity, can have a major impact on reducing high blood pressure and preventing organ damage in children and adolescents. However, suppose these are not sufficient to treat hypertension. In that case, if patients are symptomatic and/or have additional metabolic conditions such as obesity, type diabetes mellitus, or chronic kidney disease, anti-hypertensive medication must be started. Recent guidelines have provided clear guidance on the treatment of hypertension and hypertensive crisis in pediatric age. On the other hand, there are currently few specific recommendations on the treatment of isolated nocturnal hypertension and treatment-resistant hypertension. This review aims to summarize the most recent recommendations for the treatment of hypertension and hypertensive crisis in children and the last years' knowledge and experience in treating childhood isolated nocturnal hypertension and resistant hypertension of childhood.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141761601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Screening for Hypertension in Adults of a Northern Delta Province in Vietnam. 越南北部三角洲省成人高血压筛查。
IF 2.3 Q2 Medicine Pub Date : 2024-05-29 DOI: 10.2174/0115734021283836240522120929
Minh Huynh Van, Thuy Le Thi Bich, Nguyen Tran Tu, Sang Phan Văn, Yến Hoàng Thị Bạch, Tien Hoang Anh

Background: The proportion of people with hypertension is increasing, and those affected are relatively younger. Worldwide, it is estimated that people with high blood pressure are more than 1.5 billion people. In Vietnam, from 2002 to 2008, according to a national survey on hypertension and its risk factors within the prevention and control of cardiovascular disease program, the prevalence of hypertension was 25.1%. This is alarming because high blood pressure can cause serious complications, including death.

Objective: The study aimed to explore the blood pressure characteristics and hypertension prevalence in adults in a northern delta province of Vietnam, and describe some risk factors in hypertensive subjects screened through the program.

Methods: This was a cross-sectional study collecting data from people aged 18 years or older in 10 cantons and the city of Nam Dinh from July 15th to July 31st, 2020. Using semi-automatic OMRON sphygmomanometers, sitting blood pressure was measured three times according to standardized methods specified by the Ministry of Health and two National Vascular Societies.

Results: Blood pressure screening of 183,632 adults included 84,438 males, which accounted for 45.98%, with an average age of 60.36 ± 13.18 years. The estimated prevalence of hypertension was 27.20% (95% CI: 27.00% - 27.41%). The older the age, the higher the rate of hypertension in both sexes; the prevalence of hypertension over 65 years was 45.36%. Hypertension grade 1 accounted for 17.14%, followed by hypertension at grade 2 at 6.69%, and grade 3 at 1.15%; notably, the percentage of prehypertension accounted for 49.64%. The percentage of treated hypertension in Nam Dinh province was 56.85%, but the percentage of uncontrolled hypertension was 85.63%.

Conclusion: The prevalence of hypertension in Nam Dinh province was relatively high (27.20%), although the number of treated patients was also high (56.85%); moreover, the proportion of uncontrolled hypertension remained extremely high (85.63%). Local campaigns and suitable interventions are required to detect hypertension in the early stages and increase awareness for treatment in the population.

背景:高血压患者的比例正在增加,而且患者相对年轻。据估计,全世界高血压患者超过 15 亿人。在越南,2002 年至 2008 年期间,根据心血管疾病预防和控制计划中的一项关于高血压及其风险因素的全国调查,高血压患病率为 25.1%。这令人担忧,因为高血压可导致严重的并发症,包括死亡:本研究旨在探讨越南北部三角洲省成年人的血压特征和高血压患病率,并描述通过该计划筛查的高血压受试者的一些风险因素:这是一项横断面研究,收集了 2020 年 7 月 15 日至 7 月 31 日期间 10 个县和南定市 18 岁及以上人群的数据。使用半自动欧姆龙血压计,按照卫生部和两个国家血管协会规定的标准化方法测量三次坐位血压:对 183 632 名成年人进行了血压筛查,其中男性 84 438 人,占 45.98%,平均年龄为 60.36 ± 13.18 岁。高血压患病率估计为 27.20%(95% CI:27.00% - 27.41%)。年龄越大,男女高血压患病率越高;65 岁以上高血压患病率为 45.36%。一级高血压占 17.14%,二级高血压占 6.69%,三级高血压占 1.15%;值得注意的是,高血压前期占 49.64%。南定省接受治疗的高血压患者占 56.85%,但未得到控制的高血压患者占 85.63%:结论:南定省的高血压发病率相对较高(27.20%),但接受治疗的患者人数也较多(56.85%);此外,未得到控制的高血压比例仍然极高(85.63%)。需要在当地开展宣传活动并采取适当的干预措施,以便在早期阶段发现高血压并提高民众的治疗意识。
{"title":"Screening for Hypertension in Adults of a Northern Delta Province in Vietnam.","authors":"Minh Huynh Van, Thuy Le Thi Bich, Nguyen Tran Tu, Sang Phan Văn, Yến Hoàng Thị Bạch, Tien Hoang Anh","doi":"10.2174/0115734021283836240522120929","DOIUrl":"https://doi.org/10.2174/0115734021283836240522120929","url":null,"abstract":"<p><strong>Background: </strong>The proportion of people with hypertension is increasing, and those affected are relatively younger. Worldwide, it is estimated that people with high blood pressure are more than 1.5 billion people. In Vietnam, from 2002 to 2008, according to a national survey on hypertension and its risk factors within the prevention and control of cardiovascular disease program, the prevalence of hypertension was 25.1%. This is alarming because high blood pressure can cause serious complications, including death.</p><p><strong>Objective: </strong>The study aimed to explore the blood pressure characteristics and hypertension prevalence in adults in a northern delta province of Vietnam, and describe some risk factors in hypertensive subjects screened through the program.</p><p><strong>Methods: </strong>This was a cross-sectional study collecting data from people aged 18 years or older in 10 cantons and the city of Nam Dinh from July 15th to July 31st, 2020. Using semi-automatic OMRON sphygmomanometers, sitting blood pressure was measured three times according to standardized methods specified by the Ministry of Health and two National Vascular Societies.</p><p><strong>Results: </strong>Blood pressure screening of 183,632 adults included 84,438 males, which accounted for 45.98%, with an average age of 60.36 ± 13.18 years. The estimated prevalence of hypertension was 27.20% (95% CI: 27.00% - 27.41%). The older the age, the higher the rate of hypertension in both sexes; the prevalence of hypertension over 65 years was 45.36%. Hypertension grade 1 accounted for 17.14%, followed by hypertension at grade 2 at 6.69%, and grade 3 at 1.15%; notably, the percentage of prehypertension accounted for 49.64%. The percentage of treated hypertension in Nam Dinh province was 56.85%, but the percentage of uncontrolled hypertension was 85.63%.</p><p><strong>Conclusion: </strong>The prevalence of hypertension in Nam Dinh province was relatively high (27.20%), although the number of treated patients was also high (56.85%); moreover, the proportion of uncontrolled hypertension remained extremely high (85.63%). Local campaigns and suitable interventions are required to detect hypertension in the early stages and increase awareness for treatment in the population.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141176409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Highlights from the New European Society of Hypertension Guidelines Document. 欧洲高血压学会新指南文件要点。
IF 2.3 Q2 Medicine Pub Date : 2024-05-16 DOI: 10.2174/0115734021309169240508110407
Guido Grassi
The present editorial will review the main recommendations included in the recentguidelines for the diagnosis and treatment of hypertension issued by the European Society of Hypertension.Emphasis will be given to some crucial issues of major relevance for current clinicalpractice, such as office and out-of-office blood pressure measurements, blood pressure thresholdand targets, combination drugs, the position of beta-blocking drugs in the therapeutic intervention,and renal denervation.
本社论将回顾欧洲高血压学会最近发布的高血压诊断和治疗指南中的主要建议,重点讨论与当前临床实践密切相关的一些关键问题,如诊室和诊室外血压测量、血压阈值和目标、联合用药、β-阻断药物在治疗干预中的地位以及肾脏去神经支配。
{"title":"Highlights from the New European Society of Hypertension Guidelines Document.","authors":"Guido Grassi","doi":"10.2174/0115734021309169240508110407","DOIUrl":"https://doi.org/10.2174/0115734021309169240508110407","url":null,"abstract":"\u0000\u0000The present editorial will review the main recommendations included in the recent\u0000guidelines for the diagnosis and treatment of hypertension issued by the European Society of Hypertension.\u0000Emphasis will be given to some crucial issues of major relevance for current clinical\u0000practice, such as office and out-of-office blood pressure measurements, blood pressure threshold\u0000and targets, combination drugs, the position of beta-blocking drugs in the therapeutic intervention,\u0000and renal denervation.\u0000","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140967032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Highlights from the New European Society of Hypertension Guidelines Document. 欧洲高血压学会新指南文件要点。
IF 2.3 Q2 Medicine Pub Date : 2024-05-16 DOI: 10.2174/0115734021309169240508110407
Guido Grassi
{"title":"Highlights from the New European Society of Hypertension Guidelines Document.","authors":"Guido Grassi","doi":"10.2174/0115734021309169240508110407","DOIUrl":"https://doi.org/10.2174/0115734021309169240508110407","url":null,"abstract":"","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140959828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting Hypertension: A Review on Pathophysiological Factors and Treatment Strategies. 针对高血压:病理生理因素和治疗策略综述》。
IF 2.3 Q2 Medicine Pub Date : 2024-03-20 DOI: 10.2174/0115734021293403240309165336
Ruhani Raj, Minakshi Garg, Anupreet Kaur

Hypertension is one of the primary causes of cardiovascular diseases and death, with a higher prevalence in low- and middle-income countries. The pathophysiology of hypertension remains complex, with 2% to 5% of patients having underlying renal or adrenal disorders. The rest are referred to as essential hypertension, with derangements in various physiological mechanisms potentially contributing to the development of essential hypertension. Hypertension elevates the risk of cardiovascular disease (CVD) events (coronary heart disease, heart failure, and stroke) and mortality. First-line therapy for hypertension is lifestyle change, which includes weight loss, a balanced diet that includes low salt and high potassium intake, physical exercise, and limitation or elimination of alcohol use. Blood pressure-lowering effects of individual lifestyle components are partially additive, enhancing the efficacy of pharmaceutical treatment. The choice to begin antihypertensive medication should be based on the level of blood pressure and the existence of a high atherosclerotic CVD risk. First-line hypertension treatment includes a thiazide or thiazide-like diuretic, an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, and a calcium channel blocker. Addressing hypertension will require continued efforts to improve access to diagnosis, treatment, and lifestyle interventions.

高血压是心血管疾病和死亡的主要原因之一,在中低收入国家发病率较高。高血压的病理生理学仍然很复杂,2% 至 5%的患者有潜在的肾脏或肾上腺疾病。其余患者被称为本质性高血压,各种生理机制的失调都可能导致本质性高血压的发生。高血压会增加心血管疾病(CVD)事件(冠心病、心力衰竭和中风)和死亡的风险。高血压的一线疗法是改变生活方式,包括减轻体重、摄入低盐高钾的均衡饮食、体育锻炼、限制或戒酒。各种生活方式的降压作用具有部分相加性,可增强药物治疗的疗效。应根据血压水平和是否存在高动脉粥样硬化性心血管疾病风险来选择是否开始服用降压药。一线高血压治疗包括噻嗪类或噻嗪类利尿剂、血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂以及钙通道阻滞剂。要解决高血压问题,就必须继续努力改善诊断、治疗和生活方式干预。
{"title":"Targeting Hypertension: A Review on Pathophysiological Factors and Treatment Strategies.","authors":"Ruhani Raj, Minakshi Garg, Anupreet Kaur","doi":"10.2174/0115734021293403240309165336","DOIUrl":"https://doi.org/10.2174/0115734021293403240309165336","url":null,"abstract":"<p><p>Hypertension is one of the primary causes of cardiovascular diseases and death, with a higher prevalence in low- and middle-income countries. The pathophysiology of hypertension remains complex, with 2% to 5% of patients having underlying renal or adrenal disorders. The rest are referred to as essential hypertension, with derangements in various physiological mechanisms potentially contributing to the development of essential hypertension. Hypertension elevates the risk of cardiovascular disease (CVD) events (coronary heart disease, heart failure, and stroke) and mortality. First-line therapy for hypertension is lifestyle change, which includes weight loss, a balanced diet that includes low salt and high potassium intake, physical exercise, and limitation or elimination of alcohol use. Blood pressure-lowering effects of individual lifestyle components are partially additive, enhancing the efficacy of pharmaceutical treatment. The choice to begin antihypertensive medication should be based on the level of blood pressure and the existence of a high atherosclerotic CVD risk. First-line hypertension treatment includes a thiazide or thiazide-like diuretic, an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, and a calcium channel blocker. Addressing hypertension will require continued efforts to improve access to diagnosis, treatment, and lifestyle interventions.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140176994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Looking at the Golden Ratio from the Blood Pressure Perspective: Assessing the Hypertensive Patients and Normotensive Subjects. 从血压角度看黄金比例:评估高血压患者和血压正常者。
IF 2.3 Q2 Medicine Pub Date : 2024-03-14 DOI: 10.2174/0115734021267721240304104447
Hasan Atmaca, Bilal Çuğlan, Zuhal Karagöz, Kenan Yalta, Ertan Yetkin

Background: The representatives of mathematical concepts and indices allied to the Golden Ratio (GR) have been shown in the human body in superimposed human hands, phalangeal lengths of the digits, human ears, and the cardiovascular system. Recently, it has been demonstrated that the systolic blood pressure (SBP) to diastolic blood pressure (DBP) ratio measured by ambulatory blood pressure monitoring (ABPM) is close to GR. Accordingly, we aimed to evaluate the ratios between the SBP, DBP, and PP in normotensive and hypertensive patients who were on medical treatment or not, to assess the existence of golden proportions in 24-hour ambulatory blood pressure monitoring results.

Material and method: Five hundred and twenty-nine patients who underwent ABPM were retrospectively enrolled in the study population. The ABPM was programmed to measure blood pressure every 30 min during the daytime and 60 min night time. Based on the ABPM results, patients were classified as hypertensive (SBP/DBP≥130/80 mmHg) and normotensive (SBP/DBP<130/80 mmHg), depending on ESC/ESH 2018 guidelines. They were also divided into two subgroups: medicated and nonmedicated. Systolic to diastolic blood pressure ratio (SBP/DBP) and diastolic blood pressure to pulse pressure (DBP/PP) were calculated in the usual fashion in all study populations and subgroups.

Results: After the exclusion of 133 patients who did not fulfill the inclusion criteria, 396 patients were included in the statistical analysis. Mean SBP/DBP ratios were 1.66±0.15 in all the study population, 1.63±0.11 in normotensive without medication, 1.66±0.13 in normotensive with medications, 1.62±0.15 in hypertensive without medication, and 1.76±0.20 with medications.

Conclusion: We have documented that SBP to DBP ratios of untreated patients, irrespective of having normal or high blood pressure, run close around the GR. However, SBP to DBP ratios of patients having antihypertensive treatment are far from the GR.

背景:与黄金比例(GR)相关的数学概念和指数的代表已在人体中的叠加人手、指骨长度、人耳和心血管系统中显示出来。最近有研究表明,通过非卧床血压监测(ABPM)测量的收缩压(SBP)与舒张压(DBP)之比接近黄金分割率。因此,我们旨在评估正常血压和高血压患者的 SBP、DBP 和 PP 之间的比率,以评估 24 小时动态血压监测结果中是否存在黄金比例:回顾性地将接受 ABPM 的 529 名患者纳入研究人群。ABPM 的程序设定为白天每 30 分钟测量一次血压,夜间每 60 分钟测量一次血压。根据 ABPM 的结果,患者被分为高血压(SBP/DBP≥130/80 mmHg)和正常血压(SBP/DBPResults:在排除 133 名不符合纳入标准的患者后,396 名患者被纳入统计分析。所有研究人群的平均 SBP/DBP 比值为 1.66±0.15,正常血压无药物治疗者为 1.63±0.11,正常血压有药物治疗者为 1.66±0.13,高血压无药物治疗者为 1.62±0.15,有药物治疗者为 1.76±0.20:我们发现,未经治疗的患者,无论血压正常或偏高,其 SBP 与 DBP 之比均接近 GR 值。然而,接受降压治疗的患者的 SBP 与 DBP 比值却与 GR 相去甚远。
{"title":"Looking at the Golden Ratio from the Blood Pressure Perspective: Assessing the Hypertensive Patients and Normotensive Subjects.","authors":"Hasan Atmaca, Bilal Çuğlan, Zuhal Karagöz, Kenan Yalta, Ertan Yetkin","doi":"10.2174/0115734021267721240304104447","DOIUrl":"https://doi.org/10.2174/0115734021267721240304104447","url":null,"abstract":"<p><strong>Background: </strong>The representatives of mathematical concepts and indices allied to the Golden Ratio (GR) have been shown in the human body in superimposed human hands, phalangeal lengths of the digits, human ears, and the cardiovascular system. Recently, it has been demonstrated that the systolic blood pressure (SBP) to diastolic blood pressure (DBP) ratio measured by ambulatory blood pressure monitoring (ABPM) is close to GR. Accordingly, we aimed to evaluate the ratios between the SBP, DBP, and PP in normotensive and hypertensive patients who were on medical treatment or not, to assess the existence of golden proportions in 24-hour ambulatory blood pressure monitoring results.</p><p><strong>Material and method: </strong>Five hundred and twenty-nine patients who underwent ABPM were retrospectively enrolled in the study population. The ABPM was programmed to measure blood pressure every 30 min during the daytime and 60 min night time. Based on the ABPM results, patients were classified as hypertensive (SBP/DBP≥130/80 mmHg) and normotensive (SBP/DBP<130/80 mmHg), depending on ESC/ESH 2018 guidelines. They were also divided into two subgroups: medicated and nonmedicated. Systolic to diastolic blood pressure ratio (SBP/DBP) and diastolic blood pressure to pulse pressure (DBP/PP) were calculated in the usual fashion in all study populations and subgroups.</p><p><strong>Results: </strong>After the exclusion of 133 patients who did not fulfill the inclusion criteria, 396 patients were included in the statistical analysis. Mean SBP/DBP ratios were 1.66±0.15 in all the study population, 1.63±0.11 in normotensive without medication, 1.66±0.13 in normotensive with medications, 1.62±0.15 in hypertensive without medication, and 1.76±0.20 with medications.</p><p><strong>Conclusion: </strong>We have documented that SBP to DBP ratios of untreated patients, irrespective of having normal or high blood pressure, run close around the GR. However, SBP to DBP ratios of patients having antihypertensive treatment are far from the GR.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140144274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Statin Therapy and Flow-Mediated Dilation: A Systematic Review and Dose-Response Meta-Analysis Using the GRADE of Data from Randomized Controlled Trials. 他汀类药物治疗与血流介导的扩张:使用随机对照试验数据 GRADE 进行的系统回顾和剂量反应元分析
IF 2.3 Q2 Medicine Pub Date : 2024-02-21 DOI: 10.2174/0115734021280797240212091416
Seyyed Mostafa Arabi, Mahla Chambari, Leila Sadat Bahrami, Saeid Hadi, Amirhossein Sahebkar

Introduction: A previous meta-analysis reported the positive effects of statin therapy on endothelial function. However, the obtained result had several limitations that necessitated updating the information in this field. Therefore, a systematic and meta-analysis review was conducted to determine whether statin therapy could improve endothelial function, as assessed by flow-- mediated dilation (FMD).

Methods: MEDLINE, SciVerse Scopus, and Clarivate Analytics Web of Science were searched to identify randomized placebo-controlled trials assessing the impact of statin therapy on FMD. A random-effects model was used for meta-analysis to calculate the mean difference in weight. Meta- regression and subgroup analyses were used to identify sources of heterogeneity. In addition, nonlinear dose-response, quality of evidence, influence analysis, and publication bias evaluation were assessed using standard methods.

Result: Thirty-five trials (41 arms) involving 2178 participants were included in the meta-analysis study. Statin treatment significantly improved FMD [weighted mean difference (WMD): 1.7%, 95% CI: 1.3-2.2, p < 0.001). However, significant heterogeneity was observed (I2=97.9%, p < 0.001). The results of the subgroup analysis showed that health status can contribute to heterogeneity. Non-linear dose-response analysis revealed the most significant improvement in FMD with atorvastatin at a dose of 20 mg/day and simvastatin at 80 mg/day.

Conclusion: Statin therapy significantly improved endothelial function, as assessed by FMD. These changes are clinically significant, but their use should be approached with caution.

导言之前的一项荟萃分析报告了他汀类药物治疗对内皮功能的积极影响。然而,所获得的结果存在一些局限性,因此有必要更新这一领域的信息。因此,我们进行了一项系统性荟萃分析综述,以确定他汀类药物治疗是否能改善内皮功能,该功能通过血流介导的扩张(FMD)进行评估:方法:检索了MEDLINE、SciVerse Scopus和Clarivate Analytics Web of Science,以确定评估他汀类药物治疗对FMD影响的随机安慰剂对照试验。荟萃分析采用随机效应模型计算体重的平均差异。元回归和亚组分析用于确定异质性的来源。此外,还使用标准方法评估了非线性剂量反应、证据质量、影响分析和发表偏倚评价:荟萃分析研究共纳入 35 项试验(41 项研究),涉及 2178 名参与者。他汀类药物治疗可明显改善 FMD [加权平均差(WMD):1.7%,95% CI:1.3-2.2,P < 0.001]。然而,观察到了明显的异质性(I2=97.9%,p < 0.001)。亚组分析结果表明,健康状况可能导致异质性。非线性剂量反应分析显示,阿托伐他汀剂量为20毫克/天时,FMD的改善最为显著;辛伐他汀剂量为80毫克/天时,FMD的改善最为显著:结论:他汀类药物治疗可明显改善内皮功能(以 FMD 评估)。结论:他汀类药物能明显改善血管内皮功能(以 FMD 评估)。这些变化具有临床意义,但应谨慎使用。
{"title":"Statin Therapy and Flow-Mediated Dilation: A Systematic Review and Dose-Response Meta-Analysis Using the GRADE of Data from Randomized Controlled Trials.","authors":"Seyyed Mostafa Arabi, Mahla Chambari, Leila Sadat Bahrami, Saeid Hadi, Amirhossein Sahebkar","doi":"10.2174/0115734021280797240212091416","DOIUrl":"https://doi.org/10.2174/0115734021280797240212091416","url":null,"abstract":"<p><strong>Introduction: </strong>A previous meta-analysis reported the positive effects of statin therapy on endothelial function. However, the obtained result had several limitations that necessitated updating the information in this field. Therefore, a systematic and meta-analysis review was conducted to determine whether statin therapy could improve endothelial function, as assessed by flow-- mediated dilation (FMD).</p><p><strong>Methods: </strong>MEDLINE, SciVerse Scopus, and Clarivate Analytics Web of Science were searched to identify randomized placebo-controlled trials assessing the impact of statin therapy on FMD. A random-effects model was used for meta-analysis to calculate the mean difference in weight. Meta- regression and subgroup analyses were used to identify sources of heterogeneity. In addition, nonlinear dose-response, quality of evidence, influence analysis, and publication bias evaluation were assessed using standard methods.</p><p><strong>Result: </strong>Thirty-five trials (41 arms) involving 2178 participants were included in the meta-analysis study. Statin treatment significantly improved FMD [weighted mean difference (WMD): 1.7%, 95% CI: 1.3-2.2, p < 0.001). However, significant heterogeneity was observed (I2=97.9%, p < 0.001). The results of the subgroup analysis showed that health status can contribute to heterogeneity. Non-linear dose-response analysis revealed the most significant improvement in FMD with atorvastatin at a dose of 20 mg/day and simvastatin at 80 mg/day.</p><p><strong>Conclusion: </strong>Statin therapy significantly improved endothelial function, as assessed by FMD. These changes are clinically significant, but their use should be approached with caution.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139933500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Montelukast Ameliorates 2K1C-Hypertension Induced Endothelial Dysfunction and Associated Vascular Dementia. 孟鲁司特能改善 2K1C 高血压诱导的内皮功能障碍及相关血管痴呆症
IF 2.3 Q2 Medicine Pub Date : 2024-01-01 DOI: 10.2174/0115734021276985231204092425
Surbhi Gupta, Prabhat Singh, Bhupesh Sharma

Background: Declined kidney function associated with hypertension is a danger for cognitive deficits, dementia, and brain injury. Cognitive decline and vascular dementia (VaD) are serious public health concerns, which highlights the urgent need for study on the risk factors for cognitive decline. Cysteinyl leukotriene (CysLT1) receptors are concerned with regulating cognition, motivation, inflammatory processes, and neurogenesis.

Objective: This research aims to examine the consequence of montelukast (specific CysLT1 antagonist) in renovascular hypertension 2-kidney-1-clip-2K1C model-triggered VaD in experimental animals.

Methods: 2K1C tactics were made to prompt renovascular hypertension in mature male rats. Morris water maze was employed to measure cognition. Mean arterial pressure (MAP), serum nitrite levels, aortic superoxide content, vascular endothelial activity, brain's oxidative stress (diminished glutathione, raised lipid peroxides), inflammatory markers (IL-10, IL-6, TNF-α), cholinergic activity (raised acetylcholinesterase), and cerebral injury (staining of 2, 3, 5- triphenylterazolium chloride) were also examined.

Results: Montelukast in doses of 5.0 and 10.0 mg kg-1 was used intraperitoneally as the treatment drug. Along with cognitive deficits, 2K1C-operated rats showed elevated MAP, endothelial dysfunction, brain oxidative stress, inflammation, and cerebral damage with diminished serum nitrite/nitrate. Montelukast therapy significantly and dose-dependently mitigated the 2K1Chypertension- provoked impaired behaviors, biochemistry, endothelial functions, and cerebral infarction.

Conclusion: The 2K1C tactic caused renovascular hypertension and associated VaD, which was mitigated via targeted regulation of CysLT1 receptors by montelukast administration. Therefore, montelukast may be taken into consideration for the evaluation of its complete potential in renovascular-hypertension-induced VaD.

背景:与高血压相关的肾功能衰退是认知障碍、痴呆和脑损伤的危险因素。认知功能衰退和血管性痴呆(VaD)是严重的公共卫生问题,因此迫切需要对认知功能衰退的风险因素进行研究。胱氨酰白三烯(CysLT1)受体涉及认知、动机、炎症过程和神经发生的调节:本研究旨在探讨孟鲁司特(特异性 CysLT1 拮抗剂)在翻新血管性高血压 2-Kidney-1-clip-2K1C 模型诱发的 VaD 实验动物中的作用。采用莫里斯水迷宫测量认知能力。同时还检测了平均动脉压(MAP)、血清亚硝酸盐水平、主动脉超氧化物含量、血管内皮活性、脑氧化应激(谷胱甘肽减少、脂质过氧化物升高)、炎症指标(IL-10、IL-6、TNF-α)、胆碱能活性(乙酰胆碱酯酶升高)和脑损伤(2,3,5-三苯基氯化三氮唑染色):腹腔注射 5.0 和 10.0 毫克/千克剂量的孟鲁司特作为治疗药物。除认知障碍外,2K1C 手术大鼠还表现出血压升高、内皮功能障碍、脑氧化应激、炎症和脑损伤,血清亚硝酸盐/硝酸盐减少。孟鲁司特治疗可明显减轻2K1C高血压引起的行为、生化、内皮功能受损和脑梗塞,且剂量依赖性强:结论:2K1C 战术会引起新血管性高血压和相关的 VaD,而通过服用孟鲁司特可以靶向调节 CysLT1 受体,从而缓解这种情况。因此,可以考虑评估孟鲁司特在新血管性高血压诱发的 VaD 中的全面潜力。
{"title":"Montelukast Ameliorates 2K1C-Hypertension Induced Endothelial Dysfunction and Associated Vascular Dementia.","authors":"Surbhi Gupta, Prabhat Singh, Bhupesh Sharma","doi":"10.2174/0115734021276985231204092425","DOIUrl":"10.2174/0115734021276985231204092425","url":null,"abstract":"<p><strong>Background: </strong>Declined kidney function associated with hypertension is a danger for cognitive deficits, dementia, and brain injury. Cognitive decline and vascular dementia (VaD) are serious public health concerns, which highlights the urgent need for study on the risk factors for cognitive decline. Cysteinyl leukotriene (CysLT<sub>1</sub>) receptors are concerned with regulating cognition, motivation, inflammatory processes, and neurogenesis.</p><p><strong>Objective: </strong>This research aims to examine the consequence of montelukast (specific CysLT<sub>1</sub> antagonist) in renovascular hypertension 2-kidney-1-clip-2K1C model-triggered VaD in experimental animals.</p><p><strong>Methods: </strong>2K1C tactics were made to prompt renovascular hypertension in mature male rats. Morris water maze was employed to measure cognition. Mean arterial pressure (MAP), serum nitrite levels, aortic superoxide content, vascular endothelial activity, brain's oxidative stress (diminished glutathione, raised lipid peroxides), inflammatory markers (IL-10, IL-6, TNF-α), cholinergic activity (raised acetylcholinesterase), and cerebral injury (staining of 2, 3, 5- triphenylterazolium chloride) were also examined.</p><p><strong>Results: </strong>Montelukast in doses of 5.0 and 10.0 mg kg<sup>-1</sup> was used intraperitoneally as the treatment drug. Along with cognitive deficits, 2K1C-operated rats showed elevated MAP, endothelial dysfunction, brain oxidative stress, inflammation, and cerebral damage with diminished serum nitrite/nitrate. Montelukast therapy significantly and dose-dependently mitigated the 2K1Chypertension- provoked impaired behaviors, biochemistry, endothelial functions, and cerebral infarction.</p><p><strong>Conclusion: </strong>The 2K1C tactic caused renovascular hypertension and associated VaD, which was mitigated via targeted regulation of CysLT<sub>1</sub> receptors by montelukast administration. Therefore, montelukast may be taken into consideration for the evaluation of its complete potential in renovascular-hypertension-induced VaD.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139404733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Current Hypertension Reviews
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1